Suppr超能文献

通过抗CD34免疫组织化学检测到的微血管侵犯作为肝移植后肝细胞癌复发的预测指标。

Microscopic vascular invasion detected by anti-CD34 immunohistochemistry as a predictor of recurrence of hepatocellular carcinoma after liver transplantation.

作者信息

Salizzoni Mauro, Romagnoli Renato, Lupo Francesco, David Ezio, Mirabella Stefano, Cerutti Elisabetta, Ottobrelli Antonio

机构信息

Chirurgia Generale 8, Centro Trapianto di Fegato, San Giovanni Battista Hospital, Turin, Italy.

出版信息

Transplantation. 2003 Sep 15;76(5):844-8. doi: 10.1097/01.TP.0000083555.06337.8E.

Abstract

BACKGROUND

Vascular invasion (VI) is the strongest risk factor for recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT). However, unlike macroscopic VI, microscopic VI has not been acknowledged as a predictor of recurrence in individual patients. This study aimed to determine whether immunohistochemical staining of the vessels could change the judgment on microscopic VI in such a way as to confer clinical relevance to the feature.

METHODS

Antibodies against the CD34 antigen (endothelial cell marker of hepatocarcinogenesis) were applied to sections from all the HCC nodules found in 136 patients who underwent LT for HCC arising from cirrhosis between 1990 and 2000. Microscopic VI at the periphery of the nodules was searched blindly by the same pathologist who had already examined hematoxylin-eosin slides. Several characteristics of the patients and of the cancers were analyzed to define their respective influence on recurrence.

RESULTS

Recurrent HCC was diagnosed in nine patients. Although 6 of the 22 patients in whom microscopic VI had been detected by hematoxylin-eosin staining developed recurrence, 8 of the 16 in whom microscopic VI was detected by anti-CD34 immunohistochemistry developed recurrence, accounting for 5-year cumulative incidences of recurrence of 34% and 70%, respectively. At multivariate analysis, relative risk for recurrence was the highest for microscopic VI found with anti-CD34 antibodies.

CONCLUSIONS

Microscopic VI detected by anti-CD34 immunohistochemistry implies an extremely high risk for HCC to recur after LT. Trials focusing on patients with evidence of microscopic VI are needed to test the efficacy of adjuvant therapies to prevent recurrence.

摘要

背景

血管侵犯(VI)是肝移植(LT)后肝细胞癌(HCC)复发的最强危险因素。然而,与宏观血管侵犯不同,微观血管侵犯尚未被认为是个体患者复发的预测指标。本研究旨在确定血管免疫组化染色是否能改变对微观血管侵犯的判断,从而使该特征具有临床相关性。

方法

将抗CD34抗原(肝癌发生的内皮细胞标志物)抗体应用于1990年至2000年间因肝硬化引起的HCC接受LT的136例患者中发现的所有HCC结节的切片。由已检查苏木精-伊红切片的同一位病理学家盲目搜索结节周边的微观血管侵犯情况。分析患者和癌症的几个特征,以确定它们对复发的各自影响。

结果

9例患者被诊断为复发性HCC。苏木精-伊红染色检测到微观血管侵犯的22例患者中有6例发生复发,而抗CD34免疫组化检测到微观血管侵犯的16例患者中有8例发生复发,5年累积复发率分别为34%和70%。多变量分析显示,抗CD34抗体检测到的微观血管侵犯的复发相对风险最高。

结论

抗CD34免疫组化检测到的微观血管侵犯意味着LT后HCC复发的风险极高。需要针对有微观血管侵犯证据的患者进行试验,以测试辅助治疗预防复发的疗效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验